Loading
Total declarations
Companies
▲ Purchases (13 ops.)
▼ Sales (1 ops.)
Latest filing published 01 May 2020 for IMMUNOMEDICS INC, €45.6M.
Filing timeline
BuySaleAvoro Capital Advisors LLC
Insider track record
Disclosed buys
13
Disclosed sells
1
Signal history
Closed purchases
Market purchases
13
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Avoro Capital Advisors LLC: trading record in brief
Avoro Capital Advisors LLC is a declared insider at 2 companies; the most frequent names are Immunomedics Inc and Mirati Therapeutics, Inc. Over a trading history stretching from 13 May 2019 to 1 May 2020, the count stands at 14 filings.
Both buying and selling appear: 13 purchases worth €134.3M, against 1 sale worth €5.7M. Taken together, the purchases exceed the sales by €128.6M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2020, the count stands at 1 purchase and no sales.
A typical purchase (the median) is worth €5.4M. Clusters matter here: 5 out of 13 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The record was last updated on 1 May 2020 with an open-market purchase (€45.6M) in Immunomedics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Avoro Capital Advisors LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
1,750,000 shares@ US$28.5047.6% of flowCommon Stock, $0.01 par value per shareSEC:0000902664-20-001946:0
Canonical exit: 30 Jul 2020 (T+90)
2,000,000 shares@ US$17.5023.5% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000902664-19-004538:0
Canonical exit: 4 Mar 2020 (T+90)
1,000,000 shares@ US$13.239.0% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000902664-19-003903:0
Canonical exit: 31 Dec 2019 (T+90)
500,000 shares@ US$14.104.8% of flowCommon StockSEC:0000902664-19-003903:1
Canonical exit: 1 Jan 2020 (T+90)
62,500 shares@ US$101.88100.0% of flowCommon Stock, $0.001 par value per shareSEC:0000902664-19-003156:0
400,000 shares@ US$13.253.5% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000902664-19-002892:0
Canonical exit: 24 Sept 2019 (T+90)
350,000 shares@ US$13.683.1% of flowCommon StockSEC:0000902664-19-002892:1
Canonical exit: 25 Sept 2019 (T+90)
250,000 shares@ US$13.842.3% of flowCommon StockSEC:0000902664-19-002892:2
Canonical exit: 26 Sept 2019 (T+90)
785,539 shares@ US$12.196.3% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000902664-19-002619:0
Canonical exit: 1 Sept 2019 (T+90)
500,000 shares@ US$12.104.0% of flowCommon StockSEC:0000902664-19-002619:1
Canonical exit: 2 Sept 2019 (T+90)
250,000 shares@ US$12.472.1% of flowCommon StockSEC:0000902664-19-002619:2
Canonical exit: 3 Sept 2019 (T+90)
500,000 shares@ US$15.075.0% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000902664-19-002373:0
Canonical exit: 11 Aug 2019 (T+90)
125,000 shares@ US$15.401.3% of flowCommon StockSEC:0000902664-19-002373:1
Canonical exit: 12 Aug 2019 (T+90)
125,000 shares@ US$14.951.2% of flowCommon StockSEC:0000902664-19-002373:2
Canonical exit: 13 Aug 2019 (T+90)
14 of 14 declarations
